NorthSea Therapeutics BV, a Dutch company established in November 2017 to exploit a licence for a NASH treatment called icosabutate, has raised €25 million in a Series A equity financing that will allow the company to run a critical Phase 2b, proof-of-concept study of the drug by the end of 2018.